Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

Provention Bio’s Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes...

Tailwinds' Take: excellent news for PRVB. Filing of IND in Q4 and approval early next year should be very big catalysts for this stock. OLDWICK,...

Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of...

OLDWICK, N.J. and TAMPERE, Finland, May 18, 2020 /PRNewswire/ --  Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

Provention Bio Reports First Quarter 2020 Financial Results and Provides Business Update

Tailwinds' Take: all systems go for tepluzimab. We expect the stock to continue performing well as the company gets closer to the anticipated approval...

Saturday Morning Ramblings…

Another great week in the market. The economy is in free-fall, unemployment is skyrocketing and stocks can't stop going up. How is this possible?...

Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay...

Tailwinds' Take: nice to see that everything remains on track for PRVB. We expect to see the filing completed by year-end with PDUFA date...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

Chardan Research Investor Call Summary

Tailwinds' Take: although PRVB remains one of my larger holdings, I haven't written much about it lately. That's because we're really in a holding...

There’s Blood In The Streets…

Normally I love my Saturday mornings. This is when I write the weekly newsletter and it gives me a chance to review the prior...

It’s Definitely a Beer Market

Sometimes a typo can hit the sweet spot, right? When I got the text that we're entering a beer market...well, let's just say that...

Provention Announces Positive Data from Phase 1b PREVAIL Study of PRV-3279

Tailwinds' Take: very positive results from this drug place PRVB in a great position of having two potential blockbuster products. OLDWICK, N.J., March 12, 2020...

Provention Bio Highlights Critical New Research Studies on Type One Diabetes

Tailwinds' Take: these are important studies as they not only demonstrate the potential market size, but they show, very importantly, that testing can and...

Slogging Through Winter

I was skiing outside Seattle last weekend. Steven's Pass ski resort, to be precise. They have gotten a lot of snow up there this...

Early Returns

New Years always brings out the prognosticator in all of us. Everyone likes to predict what the market will do, what sectors will shine...

Provention Bio Appoints Jason Hoitt as Chief Commercial Officer

Tailwinds' Take: Provention continues to build a team around the massive opportunity of tepluzimab. Hoitt has an impressive resume. We view his addition very...

What to Expect When Everyone’s Expecting (An Up Market)

What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

LD Micro Recap and Other Thoughts From Last Week

LA is usually a great place to be in December, compared to the rest of the nation. With the weather being generally sunny and...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.